Quince Therapeutics, Inc. — Director's Dealing 2021

Feb 12, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Cortexyme, Inc. (CRTX)
CIK: 0001662774
Period of Report: 2021-02-09

Reporting Person: Monohon Ted (Chief Accounting Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (right to buy)	$6.91	2029-02-05	Common Stock (55147)		Direct
Employee Stock Option (right to buy)	$54.85	2030-02-05	Common Stock (40000)		Direct
Employee Stock Option (right to buy)	$29.60	2030-12-10	Common Stock (45000)		Direct

Footnotes

F1: 25% of the shares underlying this option shall vest on the first annual anniversary of the vesting commencement date and 1/48th of the shares underlying this option shall vest monthly thereafter over 36 months.

F2: The shares subject to the option vest in 48 equal monthly installments from the vesting commencement date.